| Date | Title | Description | |
|---|---|---|---|
| 12 Mar 2024 | On business and financial situation | ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies | Download |
| 08 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 1 March and 7 March 2024 | Download |
| 07 Mar 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download |
| 01 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 23 February and 29 February 2024 | Download |
| 27 Feb 2024 | Annual Financial Reports and Audit Reports | The Company submits the 2023 Annual Financial Report | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 04 Oct 2018 | Share capital increases and reductions | Private placement capital increase addressed to institutional investors, excluding preferential subscription rights | Download |
| 02 Oct 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the third quarter of 2018 | Download |
| 24 Sep 2018 | Others on business performance and financial information | Updated information on business, financial position and risk factors | Download |
| 24 Sep 2018 | Share capital increases and reductions | Intention to raise gross proceeds by means of an offer addressed to institutional investors, excluding preferential subscription rights | Download |
| 26 Jul 2018 | Información sobre resultados | ROVI releases the 2018 first half results presentation | Download |